{"id":"NCT02220907","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes","officialTitle":"Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08","primaryCompletion":"2016-02","completion":"2016-02","firstPosted":"2014-08-20","resultsPosted":"2018-08-16","lastUpdate":"2018-11-01"},"enrollment":153,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Teneligliptin/Canagliflozin","otherNames":["Tenelia","MP-513","Canaglu","TA-7284"]}],"arms":[{"label":"Teneligliptin/Canagliflozin","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 52 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"52 Weeks","effectByArm":[{"arm":"Teneligliptin+Canagliflozin","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":["28608617"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":153},"commonTop":["Nasopharyngitis","Pollakiuria","Constipation","Eczema"]}}